The clinical data presented in this study indicate that CD19/CD22 BS Loop CAR-T cells demonstrated an 80% (4/5) ORR in r/r DLBCL patients, with four patients (80%) achieving CR and one patient (20%) achieving SD. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.